MDT

86.79

+0.46%↑

113.49

-1.49%↓

VEEV

171.56

-1.05%↓

HQY

81.28

-2.94%↓

PHR.US

9.16

+2.69%↑

MDT

86.79

+0.46%↑

113.49

-1.49%↓

VEEV

171.56

-1.05%↓

HQY

81.28

-2.94%↓

PHR.US

9.16

+2.69%↑

MDT

86.79

+0.46%↑

113.49

-1.49%↓

VEEV

171.56

-1.05%↓

HQY

81.28

-2.94%↓

PHR.US

9.16

+2.69%↑

MDT

86.79

+0.46%↑

113.49

-1.49%↓

VEEV

171.56

-1.05%↓

HQY

81.28

-2.94%↓

PHR.US

9.16

+2.69%↑

MDT

86.79

+0.46%↑

113.49

-1.49%↓

VEEV

171.56

-1.05%↓

HQY

81.28

-2.94%↓

PHR.US

9.16

+2.69%↑

Inicio・Lista de Acciones・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Abierto

SectorSanidad

1.63 1.87

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.55

Máximo

1.63

Métricas clave
By Trading Economics
Ingresos	-2.8M -16M
Ventas	-8.7M 5.5M
Margen de beneficios	-282.723
Empleados	81
EBITDA	-4.2M -15M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+140.88% upside

Dividendos
By Dow Jones
Próximas Ganancias	12 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-12M 640M
Apertura anterior	-0.24
Cierre anterior	1.63

Noticias sobre sentimiento de mercado

By Acuity

94%

3 / 349 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

0.6863 / 0.72 Soporte y Resistencia

Lexicon Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

6 abr 2026, 23:17 UTC

Ganancias

Samsung Forecasts Record First-Quarter Operating Profit

6 abr 2026, 23:00 UTC

Acciones populares

Stocks to Watch: Health Insurers, Mawson, Owlet

6 abr 2026, 22:13 UTC

Principales Movimientos del Mercado

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

6 abr 2026, 21:46 UTC

Adquisiciones, fusiones, absorciones

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

6 abr 2026, 17:09 UTC

Principales Movimientos del Mercado

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

6 abr 2026, 16:56 UTC

Noticias de Eventos Importantes

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

6 abr 2026, 14:47 UTC

Principales Movimientos del Mercado

Stereotaxis Shares Rise on FDA Clearance for Synchrony

7 abr 2026, 00:00 UTC

Noticias de Eventos Importantes

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

6 abr 2026, 23:58 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

6 abr 2026, 23:50 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

6 abr 2026, 23:36 UTC

Charlas de Mercado

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

6 abr 2026, 23:15 UTC

Charlas de Mercado

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

6 abr 2026, 22:52 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

6 abr 2026, 22:52 UTC

Charlas de Mercado

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

6 abr 2026, 22:14 UTC

Charlas de Mercado

Correction to Live Cattle Futures Article

6 abr 2026, 20:56 UTC

Charlas de Mercado

Mexican Private Consumption Fell in January -- Market Talk

6 abr 2026, 20:50 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

6 abr 2026, 20:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

6 abr 2026, 19:58 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

6 abr 2026, 19:58 UTC

Charlas de Mercado

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

6 abr 2026, 19:11 UTC

Charlas de Mercado

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

6 abr 2026, 19:06 UTC

Charlas de Mercado

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

6 abr 2026, 19:03 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

6 abr 2026, 19:03 UTC

Charlas de Mercado

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

6 abr 2026, 18:36 UTC

Adquisiciones, fusiones, absorciones

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6 abr 2026, 17:59 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

6 abr 2026, 17:13 UTC

Adquisiciones, fusiones, absorciones

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6 abr 2026, 16:33 UTC

Charlas de Mercado

Oil Futures Steady as Market Awaits Trump -- Market Talk

6 abr 2026, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

6 abr 2026, 14:59 UTC

Ganancias

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Comparación entre iguales

Cambio de precio

Lexicon Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

140.88% repunte

Estimación a 12 Meses

Media 3.83 USD 140.88%

Máximo 6 USD

Mínimo 1 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Lexicon Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

4 ratings

Comprar

Mantener

Vender

De acuerdo con 4 analistas que ofrecen calificaciones bursátiles a para Lexicon Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

0.6863 / 0.72Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentimiento

By Acuity

3 / 349 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.